A Trial of Anlotinib Combined With Docetaxel in Patients With Wild-type Advanced Non-squamous Non Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Anlotinib is a multi-target receptor tyrosine kinase inhibitor under domestic research and
development. It can inhibit angiogenesis-related kinases, such as VEGFR, FGFR, PDGFR and
tumor cell proliferation related kinase c-Kit kinase. In the Phase III study, patients who
failed at least two systemic chemotherapy (third-line or above) or were intolerant of the
drugs were treated with anlotinib or placebo. The PFS and OS in the anlotinib group were 5.37
months and 9.63 months, respectively. The placebo group PFS and OS were 1.4 months and 6.3
months. Therefore, it is envisaged to use anlotinib combined with docetaxel to treat
wild-type advanced non-squamous non small cell lung cancer to further improve the patient's
PFS or OS.